HC Wainwright & Co. Maintains Buy on Solid Biosciences, Raises Price Target to $25
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Arthur He maintains Solid Biosciences (NASDAQ:SLDB) with a Buy and raises the price target from $20 to $25.
HC Wainwright & Co. analyst Arthur He maintains Solid Biosciences (NASDAQ:SLDB) with a Buy and raises the price target from $20 to $25.